Algeta, Bayer's partner for a new prostrate cancer treatment, earlier said the German company has made an offer valuing the firm at $2.4 billion, a 27 percent premium to the stock's last close.

(Reporting by Frank Siebelt; Writing by Maria Sheahan)

Stocks treated in this article : Bayer AG, Algeta ASA